List of Adrenaclick drug patents

Adrenaclick is owned by Impax.

Adrenaclick contains Epinephrine.

Adrenaclick has a total of 4 drug patents out of which 0 drug patents have expired.

Adrenaclick was authorised for market use on 30 May, 2003.

Adrenaclick is available in injectable;intramuscular, subcutaneous dosage forms.

The generics of Adrenaclick are possible to be released after 12 April, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7297136 IMPAX Medicine injection devices and methods
Jan, 2025

(1 year, 7 months from now)

US10166334 IMPAX Medicine injection apparatuses
Jan, 2025

(1 year, 7 months from now)

US7621891 IMPAX Method and apparatus for delivering epinephrine
Feb, 2025

(1 year, 7 months from now)

US7905352 IMPAX Kits containing medicine injection devices and containers
Apr, 2027

(3 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 30 May, 2003

Treatment: NA

Dosage: INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

ADRENACLICK family patents

17

United States

3

Norway

3

South Africa

3

Canada

3

Taiwan

3

China

3

Russia

3

European Union

2

Australia

2

Brazil

2

San Marino

2

Mexico

2

Japan

1

Hong Kong

1

New Zealand

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in